BioXcel Therapeutics, Inc. (BTAI)
NASDAQ: BTAI · Real-Time Price · USD
1.660
-0.050 (-2.92%)
At close: Dec 26, 2025, 4:00 PM EST
1.680
+0.020 (1.20%)
After-hours: Dec 26, 2025, 6:40 PM EST
BioXcel Therapeutics Revenue
BioXcel Therapeutics had revenue of $98.00K in the quarter ending September 30, 2025, a decrease of -54.21%. This brings the company's revenue in the last twelve months to $752.00K, down -66.96% year-over-year. In the year 2024, BioXcel Therapeutics had annual revenue of $2.27M with 64.20% growth.
Revenue (ttm)
$752.00K
Revenue Growth
-66.96%
P/S Ratio
17.06
Revenue / Employee
$20,324
Employees
37
Market Cap
36.30M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 2.27M | 886.00K | 64.20% |
| Dec 31, 2023 | 1.38M | 1.01M | 268.00% |
| Dec 31, 2022 | 375.00K | - | - |
| Dec 31, 2021 | - | - | - |
| Dec 31, 2020 | - | - | - |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 435.16B |
| Johnson & Johnson | 92.15B |
| Merck & Co. | 64.24B |
| AbbVie | 59.64B |
| Eli Lilly and Company | 59.42B |
| AstraZeneca | 58.13B |
| Novartis AG | 56.37B |
| Novo Nordisk | 49.58B |
BTAI News
- 15 days ago - BioXcel Therapeutics, Inc. (BTAI) Discussion of Managing Acute Agitation in Schizophrenia and Bipolar Disorders at Home Transcript - Seeking Alpha
- 23 days ago - Award-Winning Journalist Anjalee Khemlani to Host Virtual Roundtable with Leading Medical Experts to Discuss Latest Developments in Treating Acute Agitation Related to Neuropsychiatric Conditions - GlobeNewsWire
- 6 weeks ago - BioXcel Therapeutics Reports Third Quarter 2025 Financial Results and Provides Update on Late-Stage Clinical Programs for Agitation in Bipolar, Schizophrenia, and Alzheimer's Disease - GlobeNewsWire
- 2 months ago - Halper Sadeh LLC Encourages BioXcel Therapeutics, Inc. Shareholders to Contact the Firm to Discuss Their Rights - Business Wire
- 2 months ago - BioXcel Therapeutics Announces Positive Results from Correlation Study Supporting SERENITY At-Home Exploratory Efficacy Outcomes - GlobeNewsWire
- 2 months ago - BioXcel Therapeutics to Ring Nasdaq Closing Bell on October 14 to Celebrate a Transformative Milestone in Neuroscience Innovation - GlobeNewsWire
- 3 months ago - BioXcel Therapeutics Regains Compliance with Nasdaq Market Value of Listed Securities Requirements - GlobeNewsWire
- 3 months ago - BioXcel Therapeutics, Inc. (BTAI) Discuses On SERENITY At-Home Pivotal Phase 3 Safety Trial Results Call (Transcript) - Seeking Alpha